エピソード

  • Gallstones
    2025/08/22

    Gallbladder Disease


    1. Gallstones: Types and Risk Factors

    Gallstones are the most common type of gallbladder disease. They are primarily categorized by their composition:

    • Cholesterol Stones: These are the "most common type in adults (composed of cholesterol monohydrate crystals)."
    • Pigment Stones: These are composed of calcium bilirubinate crystals.
    • Black Stones: Associated with "chronic hemolytic anemia."
    • Brown Stones: Associated with "biliary stasis and infection."

    Several factors increase the risk of developing gallstones:

    • Demographic Factors: "older age, female gender, pregnancy and postpartum, obesity."
    • Medical Conditions: "rapid weight loss, TPN, DM, cirrhosis, Crohn's disease."
    • Medications: "estrogen, OCP, somatostatin analogues, ceftriaxone, clofibrate."

    2. Clinical Presentation and Complications

    While gallstones can be asymptomatic, they can lead to significant symptoms and complications.

    • Asymptomatic Presentation: The risk of developing biliary pain in asymptomatic patients is low, at "2% per year."
    • Biliary Pain: This is a hallmark symptom, characterized by a "rapid onset and is typically located in the epigastrium or the right upper quadrant." The pain is "constant and lasts for several hours," despite the misnomer "biliary colic" as it is "not colicky in nature."
    • Other Complications:Cholecystitis: Inflammation of the gallbladder.
    • Choledocholithiasis: Gallstones in the common bile duct.
    • Cholangitis: Infection of the bile ducts.
    • Gallstone Pancreatitis: Inflammation of the pancreas due to a gallstone.
    • Rare Presentations:Mirizzi's Syndrome: An "impacted cystic duct stone obstructing the common hepatic duct."
    • Gallstone Ileus: A "large gallstone obstructing the terminal ileum," entering through a gallbladder-enteric fistula.
    • Bouveret's Syndrome: "Gastric outlet obstruction due to impaction of a gallstone in the pylorus or duodenum."

    3. Diagnosis of Gallbladder Disease

    • Gallbladder (GB) Ultrasound: This is the primary diagnostic tool, noted as "highly sensitive and specific for gallstones," though only "50% sensitive for choledocholithiasis."
    • Other Tests: "CT, MRI/MRCP, EUS, ERCP, HIDA" can also be used depending on the suspected condition.

    4. Treatment and Management

    • Prophylactic Cholecystectomy (Gallbladder Removal):Not Recommended: Generally "not recommended for asymptomatic gallstones in the general population, nor in patients with diabetes or chronic hemolytic anemia."
    • Recommended for Specific Groups:"Porcelain Gallbladder" (GB wall calcifications): Due to a significant risk of coexisting "GB malignancy" of "~ 20%."
    • Abnormal Pancreatobiliary Junction: Increased risk of gallbladder cancer.
    • GB Polyps > 10 mm.
    • Astronauts: "before long duration space missions (controversial)."
    • Morbidly Obese Patients Undergoing Bariatric Surgery: Cholecystectomy is "usually performed at the time of surgery." Ursodiol may be used to reduce gallstone formation in those not undergoing surgery.
    • Patients Undergoing Resection of Small Intestinal Neuroendocrine Tumors: Especially if planned for treatment with somatostatin analogues, due to increased risk of cholelithiasis.
    • Gallbladder Drainage (for sick cholecystitis patients): For patients too unwell for cholecystectomy, options include "percutaneous cholecystostomy, endoscopic ultrasound-guided gallbladder drainage, or endoscopic transpapillary drainage."

    5. Post-Cholecystectomy Complications: Bile Leak

    • Incidence: Bile leak is a complication in "~0.5-2.5% of laparoscopic cholecystectomies."
    • Common Sites: The "cystic duct stump or the ducts of Luschka" are the most frequent sites of leakage.
    • Diagnosis: Can be identified via "US, CT, HIDA, or increased bilirubin level in the peritoneal drain fluid."
    • Treatment: Primarily managed by "ERCP with stent placement, with or without a sphincterotomy."
    続きを読む 一部表示
    15 分
  • Choledochal cysts
    2025/08/22

    Choledochal Cysts

    1. Classification and Description of Choledochal Cysts

    Choledochal cysts are classified into five main types, with variations within Type I and Type IV. The classification dictates the typical appearance and influences management strategies.

    • Type IA is the most common type, accounting for 50-85% of cases. It involves "cystic dilation of the entire extrahepatic biliary tree, sparing the intrahepatic bile ducts."
    • Type II are "true diverticulum of the extrahepatic bile duct" and are relatively rare (2%).
    • Type III, known as "choledochocele," involves "dilation of the distal CBD limited to the intraduodenal part of the CBD" (1-5%).
    • Type IVa involves "multiple intra- and extrahepatic bile duct dilations (cystic or fusiform)" (15-35%).
    • Type IVb involves "multiple dilations of the extrahepatic biliary tree."
    • Type V, or "Caroli disease," refers to "multiple dilations of the intrahepatic bile ducts" (20%). Caroli syndrome combines Caroli disease with congenital hepatic fibrosis and is often associated with polycystic kidney disease.

    2. Clinical Manifestations

    Patients with choledochal cysts typically present with a triad of symptoms:

    • Abdominal pain
    • Recurrent cholangitis
    • Obstructive jaundice

    The presence of "CBD dilation without evidence of an obstructing stone or mass" should prompt consideration of choledochal cysts.


    3. Management Strategies

    Management varies significantly based on the type of cyst, with surgical excision being a common approach due to malignancy risk.

    • For Type IA, IB, IC, IVA, and IVB, the primary management is complete excision and hepaticojejunostomy. Segmental hepatectomy may be considered for localized intrahepatic involvement in Type IVA.
    • For Type II, "Simple cyst excision" is typically sufficient.
    • For Type III, "Sphincterotomy" is the recommended treatment.
    • For Type V (Caroli disease), "segmental hepatectomy if localized" is an option, with "Liver transplantation" considered for diffuse disease.

    4. High Risk of Malignancy

    A critical aspect of choledochal cysts is their significant association with malignancy, particularly cholangiocarcinoma.

    • There is an increased risk of malignancy in choledochal cysts type 1, 4, and 5.
    • The most common cancer is cholangiocarcinoma. Other associated malignancies include anaplastic, undifferentiated, and squamous cell carcinoma.
    • The overall lifetime risk of malignancy is 10-15%, which represents a "20-30-fold increase compared to the general population."
    • The risk of malignancy increases with increasing age.
    • Crucially, Type II and Type III cysts are associated with a low risk of malignancy.

    5. Association with Abnormal Pancreaticobiliary Junction (APBJ)

    Many choledochal cysts are linked to an abnormal pancreaticobiliary junction, which is a key contributor to the increased malignancy risk.

    • In this anomaly, "The pancreatic duct drains into the bile duct, leading to pancreatic reflux and chronic inflammation."
    • This reflux and inflammation "increases the risk of malignancy of the bile duct and gallbladder."


    続きを読む 一部表示
    12 分
  • Citywide Conference - Cholangitis
    2025/07/18
    Biliary Infection and Cholangitis Management1. Introduction and Importance of Early RecognitionCholangitis is a life-threatening condition that, when first described by Dr. Charcot, had a mortality rate of about 50%. While now treatable, it remains a serious concern. It is a very common, urgent consult and requires prompt recognition due to its potential to rapidly spiral into sepsis and multi-system organ failure. Early recognition is crucial for effective management and improved patient outcomes.2. Pathophysiology and Common CausesCholangitis results from an obstructed biliary tree, which increases pressure within the ducts. This increased pressure makes the ductal epithelium "leaky," increasing permeability and allowing bacteria to enter the portal and systemic circulation. While bile in healthy individuals is often sterile, interventions on the biliary system (e.g., prior sphincterotomy or surgery) can disrupt mechanisms that keep bile clean. This allows bacteria to multiply, especially when there's a foreign body like a stent or a stone, which acts as a "nidus" for bacterial growth.Common causes of obstruction leading to cholangitis include:Stones (Choledocholithiasis): These remain the top factors, accounting for up to 70% of cases.Malignancies/Tumors: Increasing due to an older population requiring various treatments. This includes cholangiocarcinoma, pancreatic head masses, and other processes in the pre-ampullary region.Post-surgical anatomyStents: Stents, while used for drainage, can become contaminated and obstructed, leading to cholangitis. As noted, "It's not until we instrument them, right, put a stent in that they can later present with cholangitis because they're stent foods."Common bacteria involved are typically gut flora, such as E. coli, Klebsiella, and other Gram-negative and anaerobic bacteria.3. Clinical Presentation and DiagnosisCharcot's Triad is the classic textbook presentation, consisting of:FeverRight upper quadrant abdominal painJaundiceHowever, only about 50% of patients present with this complete triad. Reynold's Pentad, which includes Charcot's Triad plus hypotension and altered mental state, is usually indicative of severe disease.It's important to note that elderly patients can have atypical presentations, possibly with isolated hypotension or altered mental status, similar to a UTI in the elderly.Diagnostic Approach:Labs: Blood cultures are essential and should be drawn prior to antibiotic initiation. Other important labs include CRP, bilirubin, and cholestatic enzymes (e.g., AST, ALT).Imaging:Abdominal Ultrasound: The test of choice for initial imaging due to its ease, safety, and effectiveness in detecting duct dilation and stones. If dilation or a stone is visible and skills are trusted, diagnosis can be complete.CT Scan: Not ideal for stones but good for identifying other etiologies (e.g., masses) and duct dilation.MRCP (Magnetic Resonance Cholangiopancreatography): Helpful for malignant strictures but not always needed.EUS (Endoscopic Ultrasound): Becoming a "great instrument," especially in expert hands, for patients who cannot undergo radiation imaging (e.g., pregnant patients). It allows for "hydrid diagnosis therapy with EUS ERCP concept" and can be used at the bedside for unstable ICU patients to rule out obstruction, potentially avoiding unnecessary ERCPs. EUS is a highly sensitive test for ruling out obstruction.Tokyo Guidelines for Diagnosis: These guidelines provide an algorithm requiring:One systemic evidence: Fever, leukocytosis, or other laboratory abnormality (e.g., elevated CRP).One cholestatic evidence: Total bilirubin > 2 mg/dL or elevated cholestatic enzymes (e.g., ALP, GGT).One imaging evidence: Duct dilation or identified cause of obstruction (e.g., stone, mass). Meeting these criteria provides a "strong diagnosis."4. Grading Severity and Management PlanningThe severity grading of cholangitis, typically using the Tokyo Guidelines, is crucial because it dictates the urgency of drainage and overall management.Grade 1 (Mild):Criteria: No signs of organ dysfunction.Management: Medical treatment first (antibiotics, hydration, pain management). Drainage can wait. Intervention may not be needed if a clear etiology to remove is not present (e.g., no stone to extract, no stent to replace).Grade 2 (Moderate):Criteria: Two or more "warning signs," including high fever, age ≥ 75, WBC < 4,000 or > 12,000, bilirubin > 5 mg/dL, or hypoalbuminemia.Management: Requires early drainage (within 24-48 hours).Grade 3 (Severe):Criteria: Organ failure/dysfunction (e.g., hypotension requiring pressors, respiratory failure requiring oxygen/ventilation, kidney injury, liver dysfunction, platelet dysfunction).Management: Requires urgent drainage (same day or within 24 hours). This is critical as "early or urgent drainage in these patient population actually decreases mortality" and shortens length of stay.Severity grading is dynamic: A patient initially presenting with...
    続きを読む 一部表示
    20 分